Influence of vascular load on plasma endothelin-1, cytokines and catecholamine levels in essential hypertensives

Blood Pressure

Volumn 7, Issue 3, 1998, Pages 144-148

  Cottone, Santina ^a,b   Vella, Maria C ^a   Vadalà, Anna ^a   Neri, Anna Lisa ^a   Riccobene, Raffaella ^a   Cerasola, Giovanni ^a  

^a UNIVERSITY OF PALERMO   (Italy)

^b NONE   (Italy)

Author keywords

Catecholamines; Endothelins; Growth factors; Hypertension; Vascular stress

Indexed keywords

ADRENALIN; BASIC FIBROBLAST GROWTH FACTOR; CATECHOLAMINE; CYTOKINE; ENDOTHELIN 1; NORADRENALIN; PLATELET DERIVED GROWTH FACTOR;

ADULT; ARTICLE; BLOOD PRESSURE MONITORING; BODY MASS; CATECHOLAMINE BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; ESSENTIAL HYPERTENSION; FEMALE; HAND GRIP; HEART RATE; HUMAN; ISOMETRIC EXERCISE; MALE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SHEAR STRESS; SYSTOLIC BLOOD PRESSURE;

CATECHOLAMINES; ENDOTHELIN-1; ENDOTHELIUM, VASCULAR; FIBROBLAST GROWTH FACTOR 2; HAND STRENGTH; HUMANS; HYPERTENSION; HYPERTROPHY; MUSCLE CONTRACTION; MUSCLE, SMOOTH, VASCULAR; PLATELET-DERIVED GROWTH FACTOR; STRESS; VASOCONSTRICTION;

EID: 0031661706     PISSN: 08037051     EISSN: None     Source Type: Journal    
DOI: 10.1080/080370598437349     Document Type: Article

References (22)

1. Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor produced by vascular endothelial cells. Nature 1988; 332: 411-15.
2. Yoshizumi M, Kurihara H, Fumimaro T, et al. Hemodynamic shear stress regulates endothelin gene expression in cultured endothelial cells (abst). Circulation 1988; 78: 182.
3. Appenzeller O, Wood SC. Peptides and exercise at high and low altitudes. Int J Sports Med 1992; 13: S135-40.
4. Mangieri E, Tanzilli G, Barilla F, et al. Isometric handgrip exercise increases endothelin-1 plasma levels in patients with chronic congestive heart failure. Am.J.Cardiol. 1997; 79 (9): 1261-3.
5. Letizia C, Cerci S, De Ciocchis A, et al. Plasma endotehlin-1 levels in normotensive and borderline hypertensive subjects during a standard cold pressor test. Human Hypertens 1995; 9: 903-7.
6. Eisenstein R. Angiogenesis in arteries: review. Pharmacol. Ther. 1991; 49: 1-19.
7. Reidy MA. Biology of disease: a reassessment of endothelial injury and arterial lesion formation. Lab.Invest. 1985; 53: 513-20.
8. Pickering JG, Ford CM, Tang B, Chow LH. Coordinated effects of fibroblast growth factor-2 on expression of fibrillar collagenes, matrix metalloproteinases, and tissue inhibitors of matrix metalloproteinases by human vascular smooth muscle cells. Evidence for repressed collagen production and activated degradative capacity. Arterioscler. Thromb Vasc Biol 1997; 17(3): 475-82.
9. Miao HQ, Ornitz DM, Aingorn E, et al. Modulation of fibroblast growth factor-2 receptor binding, dimerization, signaling, and angiogenic activity by a synthetic heparin-mimicking polyanionic compound. J.Clin Invest. 1997; 99 (7): 1565-75.
10. Cottone S, Vadalà A, Vella MC, et al. Comparison of Tumor Necrosis Factor and Endothelin-1 between essential and renal hypertensive patients. J.Hum.Hypertension.: in press.
11. Cristiani C, Volpi D, Ladonio A, Bertolero F. Endothelin-1 selective binding sites are downregulated by transforming growth factor-β and upregulated by basic fibroblast growth factor in a vascular smooth muscle-derived cell line. Cardiovasc. Pharmacol. 1994; 23: 988-94.
12. Bonner JC, Badgett A. Lindroos PM, Coin PG. Basic fibroblast growth factor induces expression of the PDGF receptor a on human bronchial smooth muscle cells. Am.J.Physiol. 1996; 271: L880-8.
13. Crowley ST, Ray CJ, Nawaz D, Majack RA, Horwitz LD. Multiple growth factors are released from mechanically injured vascular smooth muscle cells. Am. J. Physiol. 1995; 269: H1641-7.
14. Davenport AP, Ashby MJ, Easton P. A sensitive radio-immunoassay measuring endothelin-like immunoreactivity in human plasma : comparison of levels in patients with essential hypertension and normotensive control subjects. Clin.Sci. 1990; 78: 261-4.
15. Shiffrin EL, Thibault G. Plasma endothelin in human essential hypertension. Am.J.Hypertens. 1991; 4: 303-8.
16. Januszewicz A, Lapinski M, Symonides B, Dabrowska E, et al. Elevated endothelin-1 concentration in patients with essential hypertension. Cardiovasc Risk 1994; 1: 81-5.
17. Cottone S, Vadalà A, Nardi E, et al. Left ventricular mass and growth factors in essential hypertension. High Blood Pressure 1997; 6 (Abstr. suppl.to 3): 14.
18. de Kossodo et al WHO Collaborative Study Group. Assaying tumor necrosis factor concentrations in human serum. A WHO International Collaborative Study. J.Immunol.Methods 1995; 182: 107-14.
19. Yokokawa K, Khono M, Murakawa K, et al. Acute effects of endothelin on renal hemodynamics and blood pressure in anesthetized rats. Am J Hypertens 1989; 2: 715-7.
20. Mortensen LH, Pawloski MC, Kanagy NL, Fink GD. Chronic hypertension produced by infusion of endothelin in rats. Hypertension 1990; 15: 729-33.
21. Khono M, Yasunari K, Yokokawa K, et al. Inhibition of atrial and brain natriuretic peptides of endothelin-1 secretion after stimulation with angiotensin II and thrombin of cultured human endothelial cells. J Clin. Invest. 1991; 87: 1999-2004.
22. Cosenzi A, Sacerdote A, Bocin E, et al. Neither physical exercise nor α-1 and β-adrenergic blockade affect plasma endothelin concentrations. Am. J. Hypertens. 1996; 8: 819-22.